[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608152":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":51,"collaborators":53,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Icahn School of Medicine at Mount Sinai","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Numen SILK",null,"Patients treated with the Numen SILK coil embolization system",[13],"Device: Numen SILK coil embolization system",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Numen SILK coil embolization system","The Numen SILK coil embolization system is designed to be used in conjunction with the NumenFR detachment system. It consists of two main parts: • Introducer Sheath: The purpose of this sheath is to facilitate the introduction of the coil into the microcatheter. • Coil System: Composed of the pusher and coil implant. The coil is a permanent implant intended to occlude blood flow in vascular abnormalities. The pusher is used to deliver the coil implant to the target lesion. The NumenFR detachment system is a sterile, handheld, single-patient use device designed for use with the Numen SILK coil embolization system and is operated by two pre-loaded batteries",[9],[21],{"name":22,"affiliation":5,"role":23},"Shahram Majidi","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Sukaina Davdani","CONTACT","(212) 241-2524","Sukaina.Davdani@mountsinai.org",{"name":31,"role":27,"phone":28,"phoneExt":10,"email":32},"Samantha St Elin","Samantha.StElin@mountsinai.org",[34],{"facility":5,"status":35,"city":36,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","New York","10029","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-74.00597,40.71427,{"lat":44,"lon":43},[47,48,49],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":31,"role":27,"phone":28,"phoneExt":10,"email":32},{"name":50,"role":23,"phone":10,"phoneExt":10,"email":10},"Daryl Goldman",{"type":23,"investigatorFullName":22,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Associate Professor of Neurosurgery",[54],{"name":55,"class":56},"MicroPort NeuroTech Co., Ltd.","INDUSTRY","100608152","the-challenger-registry-100608152",false,"NCT07197840","The CHALLENGER Registry","Chronic Subdural Hematoma Treated With Numen SILK Coiling of Middle Meningeal Artery","CHALLENGER","* Age 18-98 years inclusively\n* Per CT of the head, (one of the following):\n\n  * Unilateral convexity cSDH measuring at least 10 mm in thickness OR\n  * Bilateral cSDH if only one side is considered for treatment and the contralateral side is asymptomatic and \\\u003C 5 mm in thickness.\n* cSDH at least 2\u002F3 isodense or hypodense, verified on axial CT slice used to measure the thickness of the qualifying cSDH\n* Qualifying baseline head CT performed within the 14 days prior to treatment\n* Patient or legally authorized representative agrees to be participated in the study and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization\n\nExclusion Criteria:\n\n* Secondary cause apart from trauma for the qualifying SDH, such as an underlying vascular abnormality or tumor\n* Bilateral cSDH with unknown origin of symptoms\n* Participants who underwent prior embolization of either MMA\n* Tentorial or interhemispheric SDH\n* mRS \\>4\n* On tranexamic acid\n* Intractable coagulation dysfunction or abnormal platelet count and function (pre-operative International Normalized Ratio \\[INR\\] \\> 1.5 and\u002For platelet count \\\u003C 80109\u002FL)\n* Anatomical variations that may affect the safety of MMA embolization (e.g., prominent middle MMA ophthalmic artery anastomosis)\n* Known contraindications to angiography\n* Known intolerance to occlusion procedures\n* Known vascular anatomy (small artery size) or blood flow (high vascular resistance peripheral to the feeding arteries) that precludes catheter placement or coil embolization\n* Known presence of collateral vessel pathways potentially endangering normal territories or cranial nerves during embolization.\n* Known large diameter arteriovenous shunt, i.e., where the blood does not pass through an arterial\u002Fcapillary\u002Fvenous transition but directly from an artery to a vein or presence of patent extra-to-intracranial anastomoses (where study embolization devices could pass directly into the internal carotid artery, vertebral artery, or intracranial vasculature) that cannot be addressed with coil embolization.\n* Patient has a known active systemic infection or sepsis\n* Patient is pregnant, planning to become pregnant, or lactating\n* Life expectancy of less than 6 months due to comorbid terminal conditions\n* Concurrent participation in another research protocol for investigation of an experimental therapy\n* Known or suspected to not be able to comply with the study protocol","ALL","18 Years","98 Years",{"count":69,"type":70},100,"ESTIMATED","180 Days","OBSERVATIONAL","The study is a multi-center prospective, single-arm, post-market study evaluating the efficacy and radiologic and functional outcomes associated use of the Numen SILK coils for Middle Meningeal Artery (MMA) embolization following Chronic Subdural Hematoma (cSDH) compared to surgical evacuation or medical management alone.\n\nChronic subdural hematoma is a collection of blood between the dural mater and the brain. It typically develops over time in older adults or people on anticoagulant medication. Blood slowly accumulates over time and often becomes encapsulated by a fibrous membrane over weeks or months, which can lead to the gradual development of symptoms. Middle Meningeal Artery embolization (MMAE) through coiling provides a minimally invasive option for cSDH treatment and prevention of reaccumulation and recurrence.",[75],"Chronic Subdural Hematoma","2026-07-24",{"date":78,"type":79},"2026-07-28","ACTUAL",{"date":81,"type":79},"2025-11-20",{"date":83,"type":70},"2028-03-01",{"name":5,"class":6},1]